Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights

SI-BONE -1.39%





In the last three months, 4 analysts have published ratings on SI-BONE (NASDAQ:SIBN), offering a diverse range of perspectives from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 3 0 0 0
Last 30D 0 1 0 0 0
1M Ago 1 2 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.0, a high estimate of $26.00, and a low estimate of $24.00. A decline of 1.3% from the prior average price target is evident in the current average.

price target chart

Diving into Analyst Ratings: An In-Depth Exploration

A comprehensive examination of how financial experts perceive SI-BONE is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Matt O'Brien Piper Sandler Announces Overweight $25.00 -
Drew Ranieri Morgan Stanley Raises Overweight $26.00 $25.00
Ross Osborn Cantor Fitzgerald Maintains Overweight $25.00 $25.00
Samuel Brodovsky Truist Securities Lowers Buy $24.00 $26.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SI-BONE. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of SI-BONE compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of SI-BONE's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of SI-BONE's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on SI-BONE analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know SI-BONE Better

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

SI-BONE's Economic Impact: An Analysis

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, SI-BONE showcased positive performance, achieving a revenue growth rate of 21.61% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: SI-BONE's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -28.26%, the company may face hurdles in effective cost management.

Return on Equity (ROE): SI-BONE's ROE excels beyond industry benchmarks, reaching -6.4%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): SI-BONE's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.76%, the company may face hurdles in achieving optimal financial performance.

Debt Management: SI-BONE's debt-to-equity ratio is below the industry average. With a ratio of 0.23, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via